SPY363.67+1.01 0.28%
DIA299.24+0.50 0.17%
IXIC12,205.85+111.44 0.92%

Nevro Announces Abstract Presentations For PDN And NSRBP Trials At NANS 2021 Conference Jan. 15

Company to Host Investor Briefing to Review Latest Developments REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative,

· 11/17/2020 16:04

Company to Host Investor Briefing to Review Latest Developments

REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced today that both data abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) were accepted by the North American Neuromodulation Society (NANS 2021) and will be presented at the conference on January 15, 2021. Each presentation will be ten minutes, followed by a two-minute question and answer session. Following both presentations, Nevro Chairman, CEO and President D. Keith Grossman will host a virtual investor briefing and will provide a business update and answer questions from investors about the Company's latest developments. The timing and details of the briefing will be announced before the January conference.